Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

BPAN Warriors Partners with Ciitizen to launch a groundbreaking Natural History Study to accelerate potential treatments for rare disease BPAN

The parent-led research foundation, BPAN Warriors, announced today the launch of their groundbreaking BPAN Digital Natural History Study (NHS) in partnership with Ciitizen. The new BPAN NHS aims to break down the barriers to patient participation and accessibility in the current natural history study model, while accelerating rare disease drug development.


News provided by

BPAN Warriors

Feb 18, 2021, 17:00 ET

Share this article

Share toX

Share this article

Share toX


BOCA RATON, Fla., Feb. 18, 2021 /PRNewswire-PRWeb/ -- The parent-led research foundation, BPAN Warriors, announced today the launch of their groundbreaking BPAN Digital Natural History Study (NHS) in partnership with Ciitizen, a Palo-Alto based healthcare technology company that helps patients get full control of their medical records so they can find better treatment options, participate in research and find clinical trials. The new BPAN NHS aims to break down the barriers to patient participation and accessibility in the current natural history study model, while accelerating rare disease drug development.

BPAN is a neurodegenerative disorder that leads to developmental delays, seizures, movement disorders and gradual loss of intellectual functioning. Clinical data has been and continues to be a source of incredible opportunity especially in the push toward precision medicine in rare disease. Understanding the natural history of a disease is an essential element to inform drug development. For rare diseases and patient advocacy organizations, prohibitive costs associated with existing NHS models and lack of participant access to study data, often limit patient engagement and provide insufficient natural history data, making it difficult to advance the care of children and adults living with a rare disease.

In a disease as complex as BPAN, accessing whole-health records allows us to see the entire story. Ciitizen provides us with the ability to rapidly assimilate and analyze 1000’s of points of data, across a large cohort of BPAN patients

Post this

"A single lab report or a single test result only tells part of a story. In a disease as complex as BPAN, accessing whole-health records allows us to see the entire story. Ciitizen provides us with the ability to rapidly assimilate and analyze 1000's of points of data, across a large cohort of BPAN patients," said Sarah Chisholm, Founder of BPAN Warriors. "What we know today, may fundamentally change once we see our disease collectively and may provide us critical insights that will be key in advancing BPAN treatment therapies and improving patient care."

For complex diseases such as BPAN, medical records may often be housed at multiple providers, hospitals, specialty clinics and labs. Through the Ciitizen BPAN NHS, medical records are collected, on the patient's behalf from all medical providers designated by the patient during the short onboarding process, thereby significantly reducing the caregiver burden and providing access to a larger number of medical records.

Once Ciitizen has collected the patient health records, the Ciitizen BPAN NHS platform provides patients (caregivers) direct access to their consolidated, digitized data that summarizes their whole health experience and can be used to get second opinions or share with multiple providers to facilitate and improve overall patient care.
With consent, the anonymized data is then extracted and available for clinicians, researchers and biopharma to aid in research and therapy development. Researchers will be able to access large amounts of data to help determine clinical endpoints for potential treatments.

While aggregating patients' health information is a critical first step, data standardization, accessibility and ultimately utility to the patient and research community are paramount. Understanding the patient's whole-health, shared symptoms, potential efficacy of pharmacological interventions in the treatment of symptoms, disease trajectory, and possible biomarkers, are all key in the drug development process.

BPAN Warriors joins forces with several rare disease groups including, SLC13A5 deficiency (TESS Research Foundation), SYNGAP1-related disorder (SynGAP Research Fund), Rett Syndrome (Rett Syndrome Research Trust), and FOXG1 syndrome (FOXG1 Research Foundation), who was recently awarded a $500k grant from the Chan Zuckerberg Initiative (CZI) to revolutionize the ability for patient-led advocacy groups to use machine learning to help accelerate rare disease drug development on the Ciitizen platform. Additional CNS diseases are slated for onboarding in 2021.

"Ciitizen was born when my sister Tania died from metastatic breast cancer, and I knew that she might have lived," said Anil Sethi, Chief Executive Officer of Ciitizen. "One of the biggest issues in curing any disease, especially a rare disease, is access to better data - for better endpoint selection, to predict symptom variability, and to establish natural history of disease. We are inspired by the work of advocacy groups like BPAN Warriors and are honored to partner in their fight to find treatments".

These advocacy groups understand the importance of both collaborative data practices and innovative technology that will redefine the drug development process for rare diseases. Ciitizen's digital platform will augment the existing natural history dataset in disease communities where an NHS may already exist and provide a valuable and unique service to families and researchers. Collectively, applying machine learning to aggregated data across multiple rare diseases, with shared symptoms may yield evidence for multi-disease therapies.

About BPAN Warriors: Founded in 2018, BPAN Warriors is a 501(c)(3) parent-led global organization dedicated to funding collaborative science that will expedite a cure and therapies for children and adults who are afflicted with the rare, life-limiting, neurodegenerative, genetic disorder called BPAN (beta-propeller protein-associated neurodegeneration), caused by mutations of the WDR45 gene. BPAN is bi-phasic disease characterized by severe developmental, cognitive, and physical disabilities, epilepsy, autistic features, vision and hearing loss, complex movement disorders, and rapid cognitive decline in the second or third decade of life, marked by parkinsonism, dystonia and dementia. For more information, please visit http://www.bpanwarriors.org.

About Ciitizen: Ciitizen is a leading consumer health technology company whose mission is to help patients get full control of their medical records so they can find better treatment options, participate in research and find clinical trials. As a patient-directed care platform, Ciitizen believes patients should have full control of directing the use of their data, which serves as one of the richest sources of real world evidence, unlocking new options for patients and the community. For more information, contact [email protected] and visit http://ciitizen.com/research.

Media Contact:
Sarah Chisholm, Founder, Executive Director, BPAN Warriors
[email protected]
Virginie McNamar, Project Manager, Neurological and Rare Diseases, Ciitizen
[email protected]

Media Contact

Sarah Chisholm, BPAN Warriors, +1 (561) 706-0310, [email protected]

Virginie McNamar, Ciitizen, (317) 832-3072, [email protected]

Twitter, Facebook

SOURCE BPAN Warriors

Related Links

http://www.bpanwarriors.org

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.